Retatrutide Research: What the Phase 1, Phase 2, and Phase 3 Trials Have Measured

Start here

Retatrutide is a drug candidate — not a finished medicine. Eli Lilly has been testing it in progressively larger clinical trials since 2019, and as of 2026 it is in Phase 3 (the final large-scale stage before a regulatory submission). The results published so far from Phase 1 and Phase 2 trials are the basis for this page.

The compound works by activating three hormone receptors at once: GLP-1 (which suppresses appetite and controls blood sugar), GIP (another blood-sugar hormone that also influences fat tissue), and glucagon (a hormone that raises blood sugar but also burns fat and raises energy expenditure). Activating all three together in a carefully calibrated ratio appears to produce larger weight reductions in trials than activating any one or two alone.

The numbers from the main Phase 2 trial — 24.2% mean body-weight reduction at the highest dose over 48 weeks, alongside significant improvements in blood-sugar control in people with type 2 diabetes — attracted wide scientific attention ^[1][2]. Whether those results translate fully into the larger, longer Phase 3 trials is what the current research is determining.

Triple-agonist mechanism: what the structural biology shows

Retatrutide is a 39-amino-acid synthetic peptide (molecular weight 4,731 Da) built on a GIP-based backbone. A C20 fatty-diacid acylation (a long fatty chain attached to the molecule) binds reversibly to albumin — the most abundant protein in blood plasma — which slows renal clearance and extends the half-life to approximately 6 days ^[4].

What does retatrutide do at the receptor level? Cryo-EM structures published in Cell Discovery in 2024 resolved the triple-agonist binding at 2.68, 3.26, and 2.84 angstrom resolution at GLP-1R, GIPR, and GCGR respectively ^[3]. Relative potency versus endogenous (naturally occurring) hormones was characterized as 8.9x at GIPR, 0.4x at GLP-1R, and 0.3x at GCGR. The GIPR super-potency is an intentional design feature: GIPR activation appears to amplify the weight-loss benefit of GLP-1R agonism via adipose tissue pathways, while partial GCGR agonism adds energy expenditure and hepatic lipid oxidation without triggering the hyperglycemia that would accompany full glucagon activity.

How does retatrutide work in integrated physiology? The GLP-1R arm slows gastric emptying and activates hypothalamic satiety circuits, reducing caloric intake. The GIPR arm enhances postprandial insulin secretion and modulates fat-cell metabolism. The GCGR arm increases thermogenesis (heat and energy production) via hepatic lipid mobilization. In preclinical pharmacodynamic studies, the GCGR contribution was measurable as increased energy expenditure independent of caloric restriction — a mechanism the prior dual-agonist class did not engage.

Phase 1b and Phase 2 efficacy: key trial results

Phase 1b in type 2 diabetes (Urva 2022, Lancet). The first-in-human multiple-ascending-dose trial enrolled 72 adults with type 2 diabetes (HbA1c 7.0-10.5%). Doses ranged from 0.5 mg to 3/6/9/12 mg subcutaneous once weekly over 12 weeks. Placebo-adjusted weight loss reached -8.96 kg (90% CI -11.16 to -6.75) at the highest dose group. Half-life was confirmed at approximately 6 days, validating the once-weekly design. Treatment-emergent adverse events occurred in 63% of participants, mostly GI. The safety profile was described as acceptable ^[4].

Phase 2 in obesity (Jastreboff 2023, NEJM). This 48-week randomized controlled trial enrolled 338 adults with obesity or overweight with comorbidity (51.8% male, BMI ≥30 or 27-<30 with comorbidity). At the 12 mg dose, mean body-weight change was -24.2% versus -2.1% with placebo. Effects were dose-dependent across the 1, 4, 8, and 12 mg arms. GI adverse events were dose-related and predominantly mild-to-moderate. A dose-dependent heart-rate increase peaked at approximately 24 weeks. The discontinuation rate at 12 mg was 18%, driven primarily by GI tolerability ^[1].

Phase 2 in type 2 diabetes (Rosenstock 2023, Lancet). A 36-week trial in 281 adults with type 2 diabetes using doses from 0.5 to 12 mg with stepwise escalation. At 12 mg, HbA1c was reduced by -2.02% (versus -0.01% placebo) at 24 weeks, and body weight by -16.94% (versus -3.00% placebo) at 36 weeks. Mild-to-moderate GI adverse events occurred in 35% of participants. No severe hypoglycemia was observed and there were no deaths ^[2]. Retatrutide results in greater tabular detail are on the results page.

Retatrutide references across all trials are listed on the references page.

MASLD (metabolic-associated steatotic liver disease — formerly called fatty liver) substudy (Sanyal 2024, Nature Medicine). A Phase 2a substudy enrolled 98 participants with obesity/overweight and MASLD (≥10% liver fat by MRI-PDFF, no type 2 diabetes). At 12 mg over 24 weeks, relative liver-fat reduction was -82.4%, with 86% of participants reaching normal liver fat (<5%). Reductions were sustained at 48 weeks, where the 12 mg group showed -86.0% relative liver-fat change ^[5].

Recent 2024–2025 findings: body composition, kidneys, and lipids

Body composition (Coskun 2025, Lancet Diabetes Endocrinol). A DXA (dual-energy X-ray absorptiometry — a precise whole-body scan) substudy confirmed dose-dependent reductions in total fat mass during retatrutide-induced weight loss. Lean body mass was also reduced in absolute terms, though proportionally less than fat mass. For individuals with sarcopenic risk (susceptibility to muscle loss), this warrants clinical attention ^[12].

Kidney parameters (2025, Kidney Int Rep). A Phase 2 renal-function analysis found UACR (urine albumin-to-creatinine ratio — a kidney-damage marker) reduced by approximately 37% at the 12 mg dose in the type 2 diabetes group and 28-31% at 8-12 mg in the obesity group versus placebo. Creatinine-based eGFR (estimated glomerular filtration rate — a kidney-function score) increased by 5.3-8.5 mL/min/1.73m² in the obesity group, indicating a favorable renal-safety signal ^[13].

Lipids and metabolic markers (Pearson 2026, J Clin Endocrinol Metab). Higher retatrutide doses were associated with reductions in triglycerides and insulin-resistance biomarkers. Changes in fatty acid oxidation (fat-burning at the cellular level) mediated 23.2% of the weight-reduction response in participants without type 2 diabetes ^[14].

ANGPTL3/8 reduction (Wen 2025, Diabetes Obes Metab). Reductions in ANGPTL3/8 (angiopoietin-like proteins that regulate fat metabolism and lipid levels) were observed at higher doses in both type 2 diabetes and obesity groups, paralleling reductions in triglycerides and LDL cholesterol. GCGR agonism was mechanistically implicated ^[15].

A 2025 review in Biomolecules synthesizes the Phase 1/2 pharmacology and characterizes the ~24% weight-loss magnitude as a step-change in obesity pharmacotherapy ^[6]. A separate 2025 evidence review in the World Journal of Cardiology frames triple incretin co-agonists as delivering the highest achievable weight-loss pharmacotherapy, with cardiometabolic benefits expected from the observed biochemical effects ^[11].

Ongoing Phase 3: the TRIUMPH program

TRIUMPH-2 (NCT05931367) evaluates once-weekly retatrutide in adults with obesity and type 2 diabetes ^[7]. The cardiovascular and kidney outcomes trial (NCT06383390) is examining long-term MACE (major adverse cardiovascular events) and renal endpoints ^[8]. The active-comparator trial (NCT06662383) directly compares retatrutide with tirzepatide — providing head-to-head data the Phase 2 comparisons could not offer ^[9]. A first-in-human Phase 1 study (NCT04143802) established initial safety and pharmacokinetics ^[10].

No results from the pivotal Phase 3 trials have been published as of mid-2026. Until they are, the ~24% Phase 2 weight-loss figure and the Phase 2 HbA1c reductions remain the best available efficacy data — large-effect findings from rigorously conducted trials, but from trials not sized or powered to establish regulatory approval.